

TheraSci Limited
Company Number 4348679

Balance Sheet at 31 December 2021

	2021 £	2020 £
Fixed Assets		
Intangible fixed assets	-	-
Net Assets	-	-
Capital and Reserves		
Called up share capital	3,410	3,410
Share premium account	2,911,841	2,911,841
Profit and loss account	(2,915,251)	(2,915,251)
	-	-

Statements

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

For the year ending 31 December 2021 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The directors acknowledge the following responsibilities;


- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
- For complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts were approved by the Board of Directors

on 13/08/22
And signed on their behalf by:

S. [Signature] Director

WEDNESDAY



SBEZ0340

SCT

19/10/2022

#1

COMPANIES HOUSE

TheraSci Limited
Company Number 4348679

Notes to the financial statements

1. Accounting Policies

Basis of accounting

The financial statements are prepared in accordance with the historical cost convention.

Intangible fixed assets

Licences

Licences are expensed immediately as part of research and development costs.

2. Intangible fixed assets

	Licences £
Cost	
At the beginning and end of the year	<u>938,967</u>
Amortisation	
At the beginning and end of the year	<u>938,967</u>
Net book values	
At the beginning and end of the year	<u>-</u>

3. Share capital

	2021 £	2020 £
<u>Authorised equity</u>		
400 Ordinary shares of £1 each (2020: 400)	400	400
4,600 Ordinary 'A' shares of £1 each (2020: 4,600)	<u>4,600</u>	<u>4,600</u>
	<u>5,000</u>	<u>5,000</u>
<u>Allotted, called-up and fully paid equity</u>		
300 Ordinary shares of £1 each (2020: 300)	300	300
3,110 Ordinary 'A' shares of £1 each (2020: 3,110)	<u>3,110</u>	<u>3,110</u>
	<u>3,410</u>	<u>3,410</u>

TheraSci Limited
Company Number 4348679

Notes to the financial statements

1. Accounting Policies

Basis of accounting

The financial statements are prepared in accordance with the historical cost convention.

Intangible fixed assets

Licences

Licences are expensed immediately as part of research and development costs.

2. Intangible fixed assets

	Licences £
Cost	
At the beginning and end of the year	<u>938,967</u>
Amortisation	
At the beginning and end of the year	<u>938,967</u>
Net book values	
At the beginning and end of the year	<u>-</u>

3. Share capital

	2020 £	£
<u>Authorised equity</u>		
400 Ordinary shares of £1 each (2019: 400)	400	400
4,600 Ordinary 'A' shares of £1 each (2019: 4,600)	<u>4,600</u>	<u>4,600</u>
	<u>5,000</u>	<u>5,000</u>
<u>Allotted, called-up and fully paid equity</u>		
300 Ordinary shares of £1 each (2019: 300)	300	300
3,110 Ordinary 'A' shares of £1 each (2019: 3,110)	<u>3,110</u>	<u>3,110</u>
	<u>3,410</u>	<u>3,410</u>

TheraSci Limited
Company Number 4348679

Balance Sheet at 31 December 2020

	2020 £	2019 £
Fixed Assets		
Intangible fixed assets	-	-
Net Assets		
Capital and Reserves		
Called up share capital	3,410	3,410
Share premium account	2,911,841	2,911,841
Profit and loss account	(2,915,251)	(2,915,251)

Statements

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.


For the year ending 31 December 2020 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The directors acknowledge the following responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476,
- For complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts were approved by the Board of Directors

on 08-September-2021
And signed on their behalf by:


Director
ABDOLGHANI OMARKI